Journal of Physiology & Pathology in Korean Medicine (동의생리병리학회지)

The Physiological Society of Korean Medicine and The Society of Pathology in Korean Medicine (대한동의생리학회·한의병리학회)
권호 표지

Effects of in vivo Synergism of Eunkyo-san, a Poly-Herbal Formula and Rufloxacin against Klebsiella pneumoniae Respiratory Infections

은교산(銀翹散)과 Rufloxacin의 병용투여(倂用投與)가 Klebsiella pneumoniae 호흡기감염(呼吸器感染)에 미치는 영향

  • Ho, Yen-Guey (Division of Respiratory System, College of Oriental Medicine, Daegu Haany University) ;
  • Park, Mee-Yeon (Division of Respiratory System, College of Oriental Medicine, Daegu Haany University) ;
  • Choi, Hae-Yun (Division of Respiratory System, College of Oriental Medicine, Daegu Haany University) ;
  • Kim, Jong-Dae (Division of Respiratory System, College of Oriental Medicine, Daegu Haany University) ;
  • Song, Kwang-Kyu (Division of Respiratory System, College of Oriental Medicine, Daegu Haany University)
  • 하연귀 (대구한의대 한의학과 폐계내과학교실) ;
  • 박미연 (대구한의대 한의학과 폐계내과학교실) ;
  • 최해윤 (대구한의대 한의학과 폐계내과학교실) ;
  • 김종대 (대구한의대 한의학과 폐계내과학교실) ;
  • 송광규 (대구한의대 한의학과 폐계내과학교실)
  • Published : 2005.06.25
Download PDF
⟨ Previous Next ⟩

Abstract

In order to evaluate the in vivo synergic effect of Eunkyo-san with quinolone antibiotics, rufloxacin (RUFX), the viable bacterial numbers and histopathological changes were monitored after experimental respiratory infection with Klebsiella peumoniae NCTC 9632. The obtained results were as follows : In RUFX group, the viable bacterial numbers were significantly decreased compared to those of control group and these were more dramatically decreased compared to those of single treatment with RUFX, respectively in concomitant treated groups with Eunkyo-san. In control group, severe infiltration of inflammatory cells, hemorrhage and hypertrophy of alveolar linings were demonstrated at microscopical levels. However, these abnormal histopathological changes were significantly decreased compared to those of control group in RUFX group, and these were more dramatically decreased compared to those of single treatment with RUFX, respectively in concomitant treated groups with Eunkyo-san. In RUFX group, the LSA% (luminal surface of alveolar%) were significantly increased compared to those of control group and these were more dramatically decreased compared to those of single treatment with RUFX, respectively in concomitant treated groups with Eunkyo-san. According to these results, it is considered that in vivo antibacterial activity of RUFX group was dramatically increased by concomitant use of Eunkyo-san against K. pneumoniae NCTC 9632 infection of respiratory tract.

Keywords

References

  1. 全國韓醫科大學 肺系內科學敎室編著. 東醫肺系內科學. p 85, 98, 140, 263, 282, 299, 311. 한문화사, 서울, 2002.
  2. Waldemar, G., Johanson, Jr. Chapter 55. Overview of pneumonia: Bennett l.C, Plum F., editors. Cecil Textbook of Medicine 20th ed. Philadelphia:Saunders, Co., p 411-413, 1996.
  3. Macfarlane, J.T. Pneumonia. Medicine 4. p 3732, 1991.
  4. 우준희. 폐렴의 이해. p 15, 울산대학교출판부, 서울, 1998.
  5. 강병철. The Merck Manual. p 650, 한우리, 서울, 2002
  6. 장준. 지역사회 폐렴. 대한내과학회지. 58, 129-145, 2000
  7. Ball P. Quinolone generations: natural history or natural selection? J Antimicrob Chemother 46, 17-24, 2000.
  8. Farker, K., Naber, K.G., Funfstuck, R. Fluoroquinolones : utilization in renal and urogenital tract infections. Med Klin 96, 383-390, 2001.
  9. Paladino, J.A. Is more than one quinolone needed in clinical practice? Ann Pharmacother 35, 1085-1095, 2001.
  10. 吳鞠通(楊進 編). 溫病條辦. p 47-48, 中國醫藥科技出版社, 北京, 1996.
  11. 안태호. 銀翹散과 quinolone계 항생제의 병용투여가 Streptococcus pneumomae 호흡기감염에 미치는 영향. 대구한의대학교 대학원 박사학위논문. 2002
  12. 이상준. 銀翹散과 quinolone계 항생제의 병용투여가 Streptococcus pneumoniae 호흡기감염에 미치는 영향. 대구한의대학교 대학원 박사학위논문. 2003.
  13. 서정임. 麻黃潤肺湯과 Rufloxacin의 병용투여가 Klebsiella pneumoniae 호흡기감염에 미치는 영향. 대한본초학회지 19(4):81-89, 2004.
  14. Lukas, K. Acute states in gastroenterology : spontaneous bacterial peritonitis and the acute intestinal pseudoobstruction syndrome. Cas Lek Cesk 140, 427-429, 2001.
  15. Marrie, T.J., Durant, H., Yates, L. Community-acquired pneumonia requiring hospitalization : 5-year prospective study. Rev Infect Dis 11, 586-599, 1989.
  16. 韓鏞徹. 임상호흡기학. p 137, 149, 一潮閣, 서울, 2000.
  17. Scannapieco, F.A., Mylotte, J.M. Relationships between periodontal disease and bacterial pneumonia. J Periodontol 67, 1114-1122, 1996.
  18. Andriole, V.T. The future of the quinolones. Drugs 58, 1-5, 1999.
  19. Akindele, J.A., Rotilu, I.O. Outbreak of neonatal Klebsiella septicaemia : a review of antimicrobial sensitivities. Afr J Med Med Sci 26, 51-53, 1997.
  20. Carpenter, J.L. Klebsiella pulmonary infections: occurrence at one medical center and review. Rev Infect Dis 12, 672-682, 1990.
  21. Jarvis, W.R., Munn, V.P., Highsmith, A.K., Culver, D.H., Hughes, J.M. The epidemiology of nosocomial infections caused by Klebsiella pneumoniae. Infect control 6, 68-74, 1985.
  22. Carden, D.L., Cibb, K.A. Pneumonia and lung abscess. Emerg Med Clin North Am 1, 345-370, 1983.
  23. Khaneja, M., Naprawa, J., Kumar, A, Piecuch, S. Successful treatment of late-onset infection due to resistant Klebsiella pneumoniae in an extremely low birth weight infant using ciprofloxacin. J Perinatol 19, 311-314, 1999.
  24. Anderl, J.N., Franklin, M.J., Stewart, P.S., Role of antibiotic penetration limitation in Kebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob Agents Chemother 44, 1818-1824, 2000.
  25. Brisse, S., Milatovic, D., Fluit, A.C., Verhoef, J., Schmitz, F.J. Epidemiology of quinolone resistance of Klebsiella pneumoniae and Klebsiella oxytoca in Europe. Eur J Clin Microbiol Infect Dis 19, 64-68, 2000.
  26. Lautenbach, E., Strom, B.L., Bilker, W.B., Patel, J.B., Edelstein, P.H., Fishman, N.O. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 33, 1288-1294, 2001.
  27. 김상찬, 김선희외 9명. 방제학. p 83-84. 영림사, 서울, 1999.
  28. Ravizzola, G., Pinsi, G., Pirali, F., Colombrita, D., Foresti, I., Peroni, L., Turano, A Rufloxacin (MF-934) : in vitro and in vivo antibacterial activity. Drugs Exp Clin Res 15, 11-15, 1989.
  29. Segre, G., Cerretani, D., Cerri, D., Moltoni, L. A new tricyclic fluoroquinolone, rufloxacin (MF-934), with interesting antibacterial and pharmacokinetic characteristics. Drugs Exp Clin Res 14, 747-754, 1988.
  30. Mattina, R., Cocuzza, CE., Cesana, M., Bonfiglio, G. In vitro activity of a new quinolone, rufloxacin, against nosocomial isolates. Chemotherapy 37, 260-269, 1991.
  31. Pessina, A, Gribaldo, L., Mineo, E., Neri, M.G. In vitro short-term and long-term cytotoxicity of fluoroquinolones on murine cell lines. Indian J Exp Bioi 32, 113-118, 1994.
  32. Cunha, B.A. Antibiotic resistance. Med Clin North Am 84, 1407-1429, 2000.
  33. Edlund, C., Nord, C.E. Effect of quinolones on intestinal ecology. Drugs 58, 65-70, 1999.
  34. Marchese, A., Debbia, E.A., Pesce, A., Schito, G.C. Bactericidal activity, morphological alterations, and synergistic interactions of rufloxacin, a new fluoroquinolone, alone and in combination with its N-desmethylate D derivative (MF 922). Chemotherapy 42, 90-99, 1996.
  35. Cismondo, M.R., Drago, L., Lombardi, A, Fassina, C, Cesana, M. Impact of rufloxacin and ciprofloxacin on the intestinal microflora in a germ-free mice model. Chemotherapy 41, 281-288, 1995.
  36. Cuffini, AM., Tullio, V., Allocco, A, Paizis, G., De Leo, C, Carlone, N.A. Effect of rufloxacin upon non-specific immune defences : in-vitro, ex-vivo and in-vivo results. J Antimicrob Chemother 34, 545-553, 1994.